Shire/Baxalta Merger's Benefits Doubted By Wall Street
This article was originally published in The Pink Sheet Daily
Although Shire struggled toward this merger for five months and says it will position Shire as the top rare disease company in the world, analysts question the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.
You may also be interested in...
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.